A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab

被引：0
|
作者：
Storniolo, AM
Burris, HA
Overmoyer, B
Silverman, P
Pegram, MD
Jones, SF
Peacock, NW
Loftiss, J
Koch, KM
Paul, E
Ho, PTC
机构：
[1] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA
[2] Sarah Cannon Canc Ctr, Nashville, TN USA
[3] Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA
[4] Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA
[5] GSK, Res Triangle Pk, NC USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [31] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Fujita, Tomoko
    Sugibayashi, Ko
    Murayama, Kosho
    Yamamoto, Noboru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1795 - 1804
  • [32] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Shunsuke Kondo
    Satoru Iwasa
    Takafumi Koyama
    Tomoko Fujita
    Ko Sugibayashi
    Kosho Murayama
    Noboru Yamamoto
    International Journal of Clinical Oncology, 2022, 27 : 1795 - 1804
  • [33] A single arm, multicentre, open-label phase II study of orally administered lapatinib (GW572016) as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
    Grimm, MO
    Machiels, JP
    Wülfing, C
    Richel, D
    Treiber, U
    de Groot, M
    Beuzeboc, P
    Farrell, J
    Colman, J
    El-Hariry, I
    ANNALS OF ONCOLOGY, 2005, 16 : 41 - 41
  • [34] Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability
    Potkin, SG
    Thyrum, PT
    Bera, R
    Carreon, D
    Alva, G
    Kalali, AH
    Yeh, C
    CLINICAL THERAPEUTICS, 2002, 24 (11) : 1809 - 1823
  • [35] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Trivedi, Ashit
    Mather, Omar
    Vega, Silvia
    Hutton, Shauna
    Hellawell, Jennifer
    Lee, Edward
    DRUGS IN R&D, 2022, 22 (02) : 141 - 146
  • [36] Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
    I. Kümler
    P. Grundtvig Sørensen
    J. Palshof
    E. Høgdall
    W. Skovrider-Ruminski
    S. Theile
    A. Fullerton
    P. G. Nielsen
    B. Vittrup Jensen
    D. L. Nielsen
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 169 - 178
  • [37] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Ashit Trivedi
    Omar Mather
    Silvia Vega
    Shauna Hutton
    Jennifer Hellawell
    Edward Lee
    Drugs in R&D, 2022, 22 : 141 - 146
  • [38] Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
    Kumler, I.
    Sorensen, P. Grundtvig
    Palshof, J.
    Hogdall, E.
    Skovrider-Ruminski, W.
    Theile, S.
    Fullerton, A.
    Nielsen, P. G.
    Jensen, B. Vittrup
    Nielsen, D. L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (01) : 169 - 178
  • [39] Phase 1 open-label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors
    Tamura, Tomohide
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Asahina, Hajime
    Shibata, Takashi
    Goto, Yasushi
    Tanioka, Maki
    Tamura, Yosuke
    Seki, Yoshitaka
    Chiu, Yi-Lin
    Gupta, Neeraj
    Carlson, Dawn
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [40] Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034)
    Tan, A. R.
    Jones, S. F.
    Dowlati, A.
    Levinson, K.
    Beatty, K.
    Suttle, B.
    Gibson, D.
    Arumugham, T.
    Lager, J.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345